So Nakamura

So Nakamura

Auto-generated profile, based on publicly available information

So Nakamura

Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2019 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
SNSo Nakamura
So Nakamura
YSYoshihiko Sadakari
Yoshihiko Sadakari
TOTakao Ohtsuka
Takao Ohtsuka
TOTakafumi Okayama
Takafumi Okayama
YNYohei Nakashima
Yohei Nakashima
MNMasafumi Nakamura
Masafumi Nakamura

1 February 2018 in Surgery
Verified
Journal Article
Closed access
KDKenjiro Date
Kenjiro Date
TOTakao Ohtsuka
Takao Ohtsuka
SNSo Nakamura
So Nakamura
NMNaoki Mochidome
Naoki Mochidome
YMYasuhisa Mori
Yasuhisa Mori
MNMasafumi Nakamura
Masafumi Nakamura

1 September 2015 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
NNNaoya Niwa
Naoya Niwa
KMKazuhiro Matsumoto
Kazuhiro Matsumoto
NHNozomi Hayakawa
Nozomi Hayakawa
YIYujiro Ito
Yujiro Ito
TMTakahiro Maeda
Takahiro Maeda
NTNobuyuki Tanaka
Nobuyuki Tanaka

10 May 2012 in BJU International
Verified
Journal Article
Open access
PDF file
KMKazuhiro Matsumoto
Kazuhiro Matsumoto
EKEiji Kikuchi
Eiji Kikuchi
HSHiroshi Shirakawa
Hiroshi Shirakawa
NHNozomi Hayakawa
Nozomi Hayakawa
NTNobuyuki Tanaka
Nobuyuki Tanaka
MOMototsugu Oya
Mototsugu Oya
Study Type – Therapy (case series) Level of Evidence 4 What's known on the subject? and What does the study add? So far, few previous reports have analysed the risk factors for tumour recurrence and stage progression with a special focus on BCG‐relapsing disease, defined as the recurrence after achieving a disease‐free status by initial BCG instillations for 6 months. There are no guidelines outlining a specific treatment strategy for BCG‐relapsing disease, although many BCG failure cases are attributable to BCG‐relapsing disease. In this study, additional BCG instillation was shown to decrease the subsequent tumour recurrence rate against BCG‐relapsing tumours with intermediate pathological risk features; however, a BCG‐relapsing tumour with a pathologically high risk was a significant risk factor for both subsequent tumour recurrence and stage progression. This information might identify a therapeutic strategy for BCG‐relapsing tumours. OBJECTIVE: To investigate the risk of subsequent tumour recurrence and stage progression in bacillus Calmette‐Guérin (BCG)‐relapsing non‐muscle‐invasive bladder cancer, defined as recurrence after achieving a disease‐free status for 6 months. PATIENTS AND METHODS: A total of 183 patients with BCG‐relapsing tumours were treated with conservative therapy between 1985 and 2008 at our three institutions. We analysed the association between their clinicopathological parameters and subsequent tumour recurrence or stage progression. RESULTS: Additional induction courses of BCG or anticancer drug (mitomycin C or epirubicin) instillations were performed in 119 patients and 24 patients, respectively. The remaining 40 patients did not undergo any adjuvant therapy. Multivariate analysis showed that a relapsing tumour with a pathologically high risk (defined as tumours with G3 and/or pT1 and/or concomitant carcinoma in situ ) was a significant risk factor for subsequent tumour recurrence ( P = 0.002; hazard ratio [HR] 2.15). Additional BCG instillation significantly decreased the subsequent tumour recurrence rate ( P < 0.001; HR 0.41). Multivariate analysis also showed that a relapsing tumour with a pathologically high risk was also significantly associated with stage progression ( P < 0.001; HR 8.05). CONCLUSIONS: An additional course of BCG instillation might be effective in patients with BCG‐relapsing tumours with pathologically intermediate risk. Nevertheless, some patients with high‐risk pathological features developed subsequent stage progression. Such patients should be followed up closely and counselled on the need for aggressive therapeutic options, such as radical cystectomy.

1 April 2019 in Surgery
Verified
Journal Article
Open access
YGYoshitaka Gotoh
Yoshitaka Gotoh
TOTakao Ohtsuka
Takao Ohtsuka
SNSo Nakamura
So Nakamura
KSKoji Shindo
Koji Shindo
KOKenoki Ohuchida
Kenoki Ohuchida
MNMasafumi Nakamura
Masafumi Nakamura
It is difficult to determine whether a second high-risk lesion, including pancreatic ductal adenocarcinoma or high-grade pancreatic intraepithelial neoplasm, is a metachronous multifocal lesion or represents local recurrence after resection of the first high-risk lesion. This study attempts to clarify the characteristics of second high-risk lesions in the remnant pancreas using genetic analyses. Clinicopathologic data were collected from 12 patients who underwent pancreatectomy for a second high-risk lesion in the remnant pancreas. We performed mutational and immunohistochemical analyses of 4 major genes-KRAS, TP53, CDKN2A, and SMAD4-associated with pancreatic ductal adenocarcinoma progression, as well as targeted next-generation sequencing. Mutations in the four genes in the second high-risk lesion were consistent with the first lesion in four patients but were inconsistent in the remaining eight patients, and thus we considered that the latter eight patients likely had metachronous multifocal high-risk lesions and the other four patients had local recurrence. The estimated cumulative recurrence rate after resection of the second high-risk lesion was greater in the local recurrence group compared with the metachronous multifocal group, and the estimated cumulative disease-specific survival rate was greater in the metachronous multifocal group. Targeted next-generation sequencing demonstrated that the second lesions in the metachronous multifocal high-risk lesion group showed differences in founder mutations compared with the first lesion. In the local recurrence group, the founder mutations in the second lesion were common with those in the first lesion. Genetic assessment might help discriminate metachronous multifocal high-risk lesions from local recurrence.

10 April 2020 in Surgical Case Reports
Verified
Journal Article
Open access
PDF file
TAToshiya Abe
Toshiya Abe
HSHiroshi Sakai
Hiroshi Sakai
MHMasataka Hayashi
Masataka Hayashi
SNSo Nakamura
So Nakamura
STShin Takesue
Shin Takesue
TNToru Nakano
Toru Nakano
Background: Intramural metastasis is rare in colorectal cancer, especially metastasis of ascending colon cancer to the appendix. Case presentation: A 64-year-old man was admitted to our hospital for surgery for ascending colon cancer detected by medical examination. Colonoscopy identified a type-2 tumor in the ascending colon, which was diagnosed as adenocarcinoma. Abdominal computed tomography revealed focal thickening of the ascending colon and middle of the appendix and swelling of the lymph nodes around the ileocolic artery. The patient underwent laparoscopic right hemi-colectomy with D3 lymph node dissection. Histopathological findings revealed that the ascending colon cancer was moderately differentiated adenocarcinoma with lymphatic and vascular invasion (stage IIIB; pT3N2M0). Additionally, moderately differentiated adenocarcinoma was observed mainly in the submucosa and muscularis propria of the appendix, which was approximately 10 cm proximal to the ascending colon cancer. These findings indicated intramural metastasis to the appendix from the ascending colon cancer. The patient experienced recurrence with lung metastasis 2.5 years after the first surgery. Conclusions: Intramural metastasis of ascending colon cancer to the appendix is extremely rare. Because the risk of recurrence and the prognosis for intramural metastasis has not been clarified, careful follow-up is recommended.